Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 5;8(1):56–65. doi: 10.1093/gastro/goz060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — The number of mice that developed liver metastasis of colon cancer through splenic tumor-cell injection (5 × 10⁴ CT26 cells) in different treatment groups. The liver metastasis of colon cancer was observed only in two of six mice in the CLM-CTX1, CLM-CTX2, and CLM-CTX3 groups. Macroscopic liver metastasis of colon cancer was observed in all mice in the CLM group. No macroscopic and microscopic liver metastases were observed in the normal group. Mice in the CLM-CTX1 group (n = 6) were intraperitoneally injected with CTX (20 mg/kg) post surgery immediately. Mice in the CLM-CTX2 group (n = 6) were intraperitoneally injected with CTX (20 mg/kg) on Days 0 and 7 post surgery. Mice in the CLM-CTX3 group (n = 6) were intraperitoneally injected with CTX (20 mg/kg) on Days 0, 7, and 14 post surgery. The mice of the liver metastasis only (CLM) group (n = 6) were not injected with CTX. CLM, colon-cancer liver metastasis; CLM-CTX, colon-cancer liver metastasis-cyclophosphamide; CTX, cyclophosphamide.